Daphne Day

View Scopus Profile

Research activity per year

If you made any changes in Pure these will be visible here soon.

1 Finished
16 Active

A Phase 1 Dose Escalation and Dose Expansion Open-label, Multicenter, Study of OP-1250 in Combination with the CDK4/6 Inhibitor Palbociclib in Adult Subjects with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer
Day, D.
16/11/21 → 15/11/26
Project: Research
A Phase I/II Trial of EMB-02, a Bi-specific Antibody against PD-1 and LAG3, in Patients with Advanced Solid Tumors
Day, D.
27/10/21 → 26/10/26
Project: Research
A Phase II, Open Label, Multicenter Study Of Olinvacimab In Combination with Pembrolizumab In Patients With Metastatic Triple-Negative Breast Cancer
Day, D.
30/09/21 → 29/09/26
Project: Research
A Phase 1 bioequivalence study between the current commercial formulation and the proposed soft gel capsule formulation of talazoparib, and food effect study for the proposed talazoparib soft gel capsule formulation in participants with advanced solid tumor
Day, D.
13/01/21 → 12/01/26
Project: Research
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus standard of care chemotherapy and levnatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and immunotherapy (PD-1/PD-L1 inhibitors) (LEAP-009)
Day, D.
28/08/20 → 27/08/25
Project: Research

12 Article
4 Meeting Abstract
2 Chapter (Book)
2 Editorial
More
- 2 Review Article
- 1 Comment / Debate

COVID-19 vaccination rates, intent, and hesitancy in patients with solid organ and blood cancers: A multicenter study
Nguyen, M., Bain, N., Grech, L., Choi, T., Harris, S., Chau, H., Freeman, D., Kwok, A., Williams, J., McCartney, A., Webber, K., Day, D. & Segelov, E., 2022, (Accepted/In press) In: Asia-Pacific Journal of Clinical Oncology. 8 p.
Research output: Contribution to journal › Article › Research › peer-review

1 Citation (Scopus)
Lower COVID-19 vaccination rates amongst Australians with gastrointestinal (GI) compared to other cancers
Nguyen, M., Bain, N., Grech, L. B., Hamad, N., Bryan, C., Blennerhassett, R., Nott, L. M., Harris, S., Nguyen, M. H. C., Underhill, C., Williams, J., Kwok, A., McCartney, A., Webber, K., Day, D. & Segelov, E., Feb 2022, In: Journal of Clinical Oncology. 40, 4 suppl, p. 648 1 p.
Research output: Contribution to journal › Meeting Abstract › Other › peer-review

Open Access
Australian CANcer patients’ perspectives on coronavirus VACCination Survey (CANVACCS): Short Messaging Service recruitment outcomes
Harris, S., Chau, H., Chan, B. A., Offer, C., Donohue, C., Kwok, A., Nguyen, M., Bain, N., Grech, L. B., Day, D., McCartney, A., Webber, K., Luong, V., McDevitt, T. & Segelov, E., 11 Nov 2021, In: Asia-Pacific Journal of Clinical Oncology. 17, Suppl 9, p. 146-147 2 p.
Research output: Contribution to journal › Meeting Abstract › Other › peer-review

Open Access
File
Enhanced toxicity with CDK 4/6 inhibitors and palliative radiotherapy: Non-consecutive case series and review of the literature
David, S., Ho, G., Day, D., Harris, M., Tan, J., Goel, S., Hanna, G. G., Srivastava, R., Kruss, G., McDowell, L. & White, M., Jan 2021, In: Translational Oncology. 14, 1, 7 p., 100939.
Research output: Contribution to journal › Article › Research › peer-review

Open Access

2 Citations (Scopus)
Recruitment, outcomes, and toxicity trends in phase I oncology trials: Six-year experience in a large institution
Menon, S., Davies, A., Frentzas, S., Hawkins, C. A., Segelov, E., Day, D. & Markman, B., Feb 2021, In: Cancer Reports. 5, 2, 8 p., e1465.
Research output: Contribution to journal › Article › Research › peer-review

Open Access

Daphne Day

Network

Dive into details

A Phase 1 Dose Escalation and Dose Expansion Open-label, Multicenter, Study of OP-1250 in Combination with the CDK4/6 Inhibitor Palbociclib in Adult Subjects with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer

A Phase I/II Trial of EMB-02, a Bi-specific Antibody against PD-1 and LAG3, in Patients with Advanced Solid Tumors

A Phase II, Open Label, Multicenter Study Of Olinvacimab In Combination with Pembrolizumab In Patients With Metastatic Triple-Negative Breast Cancer

A Phase 1 bioequivalence study between the current commercial formulation and the proposed soft gel capsule formulation of talazoparib, and food effect study for the proposed talazoparib soft gel capsule formulation in participants with advanced solid tumor

COVID-19 vaccination rates, intent, and hesitancy in patients with solid organ and blood cancers: A multicenter study

Lower COVID-19 vaccination rates amongst Australians with gastrointestinal (GI) compared to other cancers

Australian CANcer patients’ perspectives on coronavirus VACCination Survey (CANVACCS): Short Messaging Service recruitment outcomes

Enhanced toxicity with CDK 4/6 inhibitors and palliative radiotherapy: Non-consecutive case series and review of the literature

Recruitment, outcomes, and toxicity trends in phase I oncology trials: Six-year experience in a large institution

Daphne Day

Network

Projects

Research output